Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027802 · ClinicalTrials.gov registry record · Phase 3
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
A Phase 3 study of Fibrodysplasia Ossificans Progressiva (FOP), sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
- 13
- Study locations
NCT05027802 is a Phase 3 study of Fibrodysplasia Ossificans Progressiva (FOP) that has completed, run by Ipsen. The registered enrollment target is 61 participants. The trial reports 13 study locations across 6 states.
The verdict
NCT05027802, a Phase 3 study of Fibrodysplasia Ossificans Progressiva (FOP), has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
- 13
- Study locations
Study Summary
The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.
Conditions Studied
Interventions
- DRUG Palovarotene
Study Locations (13)
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
- Toronto General Hospital - Toronto
- Groupe Hospitalier Necker Enfants Malades - Paris
- Istituto Giannina Gaslini - Genoa
- Hospital Universitario Ramon y Cajal - Colmenar Viejo
- Norrlands Universitetssjukhus - Umeå
- Royal National Orthopaedic Hospital - London
Pennsylvania
- Children's Hospital of Philidelphia - Philadelphia
- The Perelman School of Medicine - The University of Pennsylvania - Philadelphia
California
- University of California San Francisco (UCSF) - San Francisco
Minnesota
- Mayo Clinic - Rochester
New South Wales
- Royal North Shore Hospital - Saint Leonards
São Paulo
- Hospital Israelita Albert Einstein - Morumbi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027802
The ClinicalTrials.gov registry entry for NCT05027802 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrodysplasia Ossificans Progressiva (FOP) appearing as the primary indexed condition, and to 1 intervention - of which Palovarotene is the first listed.
NCT05027802 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Other, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT05027802 about?
NCT05027802 is a clinical study titled "A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.". The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202...
What is the current status of trial NCT05027802?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2022-03-14. Estimated completion is 2024-11-30.
What conditions does trial NCT05027802 study?
This clinical trial studies the following conditions: Fibrodysplasia Ossificans Progressiva (FOP).
What interventions are being tested in trial NCT05027802?
The interventions under investigation include: Palovarotene (DRUG).
Who is sponsoring clinical trial NCT05027802?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05027802 being conducted?
This trial has 13 study locations across California, Minnesota, Pennsylvania, New South Wales, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrodysplasia Ossificans Progressiva (FOP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.